Stock Movers Eli Lilly Rises, Shake Shack Declines, Abercrombie & Fitch Sinks
Jan 12, 2026
Eli Lilly anticipates regulatory approval for its weight-loss pill by mid-2026, stirring excitement in the pharmaceutical market. Meanwhile, Shake Shack faces challenges with disappointing Q4 sales, blaming poor weather for keeping customers away. On the retail front, Abercrombie & Fitch's shares plunged 18% after holiday sales fell short of expectations, raising concerns about the overall retail landscape. The conversation also touches on the evolving trends in casual dining and the impact of delivery services on food preferences.
AI Snips
Chapters
Transcript
Episode notes
Oral GLP-1s Could Expand Market Access
- Eli Lilly expects its oral GLP-1 pill could gain US approval as early as Q2 2026, expanding access beyond injections.
- Novo Nordisk and Lilly together serve 10–15 million U.S. patients while ~110 million Americans live with obesity, signaling large unmet demand.
Weather, Travel, And Changing Demand Hit Shake Shack
- Shake Shack reported preliminary Q4 revenue below estimates and blamed inclement weather for lower traffic.
- Hosts suggested broader consumer shifts and travel patterns may also be reducing demand for treat-based eats like Shake Shack.
Category Placement Shapes Investor View
- Hosts debated whether Shake Shack fits the 'fast-casual' category, noting its positioning as an indulgent dinner option.
- That positioning may influence investor perceptions and customer behavior versus delivery-friendly competitors.